• Chetboul V
  • SPECanin 2002
  • Novembre 2002
  • : Cardiologie
  • : Chien, chat
  • : Bibliographie

1 - Consensus recommendations for heart failure. Am. J. Cardiol. 1999;83(2A):1A-35A.
2 - Covit AB, Schaer GL, Sealey JE et coll. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am. J. Med. 1983;75(3):445-447.
3 - Ettinger SJ, Benitz AM, Ericsson GF et coll. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J. Amer. Vet. Med. Assn. 1998;213:1573-1577.
4 - Ferguson DW, Berg WJ, Sanders JS et coll. Sympatho-inhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989;80(1):65-77.
5 - Ferguson DW. Digitalis and neurohormonal abnormalities in heart failure and implications for therapy. Am. J. Cardiol. 1992;69(18):24G-32G; discussion 32G-33G.
6 - Fukutomi T, Satoh K, Ogoshi S et coll. Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs. Coron. Artery Dis. 2000;11(1):83-90.
7 - Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure ? Circulation. 1991;84,2181-2186.
8 - Gierke KD, Perrier D, Mayersohn M et coll. Digoxin disposition kinetics in dogs before and during azotemia. J. Pharm. Exp. Ther. 1978;205:459-464.
9 - Goto Y, Hata K. Mechanoenergetic effect of pimobendan in failing dog hearts. Heart Vessels. 1997;(Suppl 12):103-105.
10 - Hamlin RL. Clinical toxicology of cardiovascular drugs. Vet. Clin. N. Amer.-Small Anim. Pract. 1990;20(2):469-481.
11 - Imbs J-L, Grima M, Stephan D. Resistance aux diurétiques. Arch. Mal. Coeur. 1998;91(11):1383-1388.
12 - Ishiki R, Ishihara T, Izawa H et coll. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J. Cardiovasc. Pharmacol. 2000;35(6):897-905.
13 - Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation. 1994;89:2297-2307.
14 - Juillière Y. Digitaliques, diurétiques et vasodilatateurs. Rev. Prat. 1997;47:2125-2129.
15 - Kittleson MD, Eyster GE, Knowlen GG et coll. Efficacy of digoxin administration in dogs with idiopathic congestive cardiomyoapthy . J. Amer. Vet. Med. Assn. 1985,186:162.
16 - Kittleson MD. Management of heart failure. In: Kittleson's small animal cardiovascular medicine, 1999, WB Saunders company. Philadelphia, chp 10:150-194.
17 - Kubo SH. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Cardiology. 1997;88(Suppl 2):21-27.
18 - Linz W, Scholkens BA. A specific béta 2-bradykinin receptor antagonist HOE140 abolishes the antihypertrophic effects of ramipril. Br. J. Pharmacol. 1992;105:771-772.
19 - Lubsen J, Just H, Hjalmarsson AC et coll. Effect of pimobendan on exercise capacity in patients with heart failure : main results from the pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76(3):223-31.
20 - Matsumori A. The use of cytokine inhibitors. A new therapeutic insight into heart failure. Int. J. Cardiol. 1997;62(Suppl 1)S3-S12.
21 - Moïse NS. Diagnosis and management of canine antiarythmias. In: Fox Sisson Moise's Textbook of feline and canine cardiology, principles and clinical practice, 1999, WB Saunders company. Philadelphia. chp 18:331-385.
22 - Muir WW, Sams RS, Moïse NS. Pharmacology and pharmacocinetics of antiarythmic drugs. In: Fox Sisson Moïse's Textbook of feline and canine cardiology, principles and clinical practice, 1999, WB Saunders company. Philadelphia. chp 17:307-330.
23 - Packer M, Gheorghiade M, Young JB et coll, for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure not treated with converting enzyme inhibitors. N. Engl. J. Med. 1993;329:1-7.
24 - Packer M, Colucci WS, Sackner-Bernsteins JD et coll, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation. 1996;94:2793-2799.
25 - Pouchelon JL, Gaillot H. Un cas de toux induite par un inhibiteur de l'enzyme de conversion de l'angiotensine chez un chien. Rec. Méd. Vét. 1993;169:799-803.
26 - Rocha R, Chander PN, Khanna K, et coll. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension, 1998;31:451-458.
27 - Sisson D, Kittleson MD. Management of heart failure : principles of treatment, therapeutic strategies, and pharmacology. In: Fox Sisson Moïse's Textbook of feline and canine cardiology, principles and clinical practice, 1999, WB Saunders company. Philadelphia. chp 12:216-250.
28 - Smith CA. Current concepts : looking for consensus in treatment of cardiac disease. J. Amer. Vet. Med. Assn. 1995;206(3):307-312.
29 - Takahashi R, Endoh M. Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J. Cardiovasc. Pharmacol. 2001;37(2):209-18.
30 - The Bench (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term trial. J. Vet. Cardiol. 1999;1:7-18.
31 - The Captopril-digoxine Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild heart failure. JAMA. 1988;259:539-544.
32 - The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure : results of the Cooperative Veterinary Enalapril Study Group. J. Vet. Intern. Med. 1995;9:243-252.
33 - The Digitalis Intervention Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997;336,525-533.
34 - The IMPROVE Study Investigators. The acute and short-term hemodynamic, echocardiographic and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicentric Prospective Veterinary Evaluation for enalapril. J. Vet. Intern. Med. 1995;9:234-242.
35 - The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992;327:685-691.
36 - The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 1996;78:902-907.
37 - Uretsky BF, Young JB, Shahidi FE et al, on behalf on the PROVED Investigate group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J. Am. Coll. Cardiol. 1993;22:955-962.

a. Fuentes LV, Kleemann R, Justus A et coll. The effect of a novel inodilator pimobendan on heart failure status in Cocker Spaniels and Dobermans with idiopathic dilated cardiomyopathy. 41st British Small Animal Veterinary Congress, Birmingham, 1998:284.
b. Kvart C, Häggström J, Pedersen HD. ACE inhibition in asymptomatic MR dogs: results from a 4-year prospective double-blind, placebo-controlled, monotherapy trial (SVEP = Scandinavian Veterinary Enalapril Prevention Trial). Proceedings 18th AVCIM, Seattle, 2000:137.
c. Lombard CW. Therapy of congestive heart failure in dogs with pimobendan. Proceedings 18th AVCIM, Seattle, 2000:107.

À Lire également
- Vandaële E. Traitement de l'insuffisance cardiaque congestive. Le pimobendane, un vasodilatateur inotrope. Point Vét. 2001;32(216):14.
- Le Bobinnec G. Le suivi thérapeutique du chien insuffisant cardiaque. Point Vét. 1998;29(188):33-43.

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d’intérêts.X
Pour en savoir plus et paramétrer les cookies...